Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer
It is difficult to identify cancer driver genes in cancers, for instance BRCA1 mutated breast cancer, that are characterised by large scale genomic alterations. Here, the authors develop genetically engineered mouse models of BRCA1-deficient breast cancer that allow highthroughput in vivo perturbati...
Guardado en:
Autores principales: | Stefano Annunziato, Julian R. de Ruiter, Linda Henneman, Chiara S. Brambillasca, Catrin Lutz, François Vaillant, Federica Ferrante, Anne Paulien Drenth, Eline van der Burg, Bjørn Siteur, Bas van Gerwen, Roebi de Bruijn, Martine H. van Miltenburg, Ivo J. Huijbers, Marieke van de Ven, Jane E. Visvader, Geoffrey J. Lindeman, Lodewyk F. A. Wessels, Jos Jonkers |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d9ac65cbd345403caaf37726c9a7d740 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Translational oncogenomics
Publicado: (2006) -
Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin
por: Koen Schipper, et al.
Publicado: (2019) -
What matters most to patients? Participative provider care and staff courtesy
por: Andrew Van de Ven
Publicado: (2014) -
RUBIC identifies driver genes by detecting recurrent DNA copy number breaks
por: Ewald van Dyk, et al.
Publicado: (2016) -
Essential components of a successful doctoral program in nanomedicine
por: van de Ven AL, et al.
Publicado: (2014)